Dermatology & Plastic Surgery Institute Outcomes
Surgical Quality Improvement
Dermatology & Plastic Surgery Institute Outcomes
Dermatology & Plastic Surgery Institute Surgery ACS NSQIP Outcomes
January 1, 2022 – December 31, 2022
The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) objectively measures and reports risk-adjusted surgical outcomes based on a defined sampling and abstraction methodology. These outcomes data reflect Cleveland Clinic’s Dermatology & Plastic Surgery Institute surgery ACS NSQIP performance benchmarked against 468 participating sites.
| Dermatology & Plastic Surgery (468 Sites) | N | Observed | Expected |
|---|---|---|---|
| 30 Day Morbidity | 351 | 3.70% | 5.64% |
| Cardiac | 351 | 0.00% | 0.05% |
| Pneumonia | 351 | 0.00% | 0.07% |
| Ventilator > 48 Hours | 351 | 0.00% | 0.01% |
| Deep Vein Thrombosis (DVT) / Pulmonary Embolus | 351 | 0.85% | 0.45% |
| Renal Failure | 351 | 0.00% | 0.11% |
| Urinary Tract Infection (UTI) | 351 | 0.28% | 0.23% |
| Surgical Site Infection (SSI) | 349 | 3.15% | 4.47% |
| Sepsis | 351 | 0.28% | 0.33% |
| C.diff Colitis | 351 | 0.00% | 0.06% |
| Unplanned Reoperation | 351 | 5.70% | 5.29% |
| Unplanned Readmissionᵃ | 351 | 5.41% | 2.79% |
American College of Surgeons National Surgical Quality Improvement Program, 2023.
ACS NSQIP® Semiannual Report July 3, 2023, Chicago: American College of Surgeons.
ᵃIdentified as a statistical outlier (higher than expected) by the ACS NSQIP hierarchical model.
